Tiespectus for Age-Related Macular Degeneration

(TORRONTES Trial)

This trial tests a new treatment called tiespectus to determine its effectiveness for neovascular age-related macular degeneration (NVAMD), a serious eye condition that affects vision. Researchers aim to compare tiespectus with the usual treatment, aflibercept. Participants will receive either a low or high dose of tiespectus or the standard treatment, aflibercept, to assess their effectiveness. Individuals recently diagnosed with NVAMD who have not yet received treatment may be suitable candidates for this trial. As a Phase 2 trial, this research focuses on evaluating tiespectus's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. However, if you have previously received anti-VEGF therapy or other intravitreal therapy in the study eye, you may not be eligible to participate.

Research has shown that tiespectus, also known as MK-8748 or EYE201, may help treat eye conditions like neovascular age-related macular degeneration (NVAMD). In earlier studies, researchers tested tiespectus in both low and high doses. These studies found improvements in vision and eye health without serious side effects, and participants generally tolerated both doses well.

No major safety issues have been reported so far, suggesting that tiespectus might be a safe option for treating NVAMD. However, this trial is in its later stages, meaning researchers have already collected some safety data but are still studying its effects in more detail.

Researchers are excited about Tiespectus for age-related macular degeneration because it offers a potentially more personalized approach to treatment. Unlike current standard treatments like Aflibercept, which have a fixed dosing schedule, Tiespectus can be adjusted based on the individual's response after the initial phase. This means Tiespectus could maintain or improve vision with fewer injections, tailoring therapy to the patient's needs. Additionally, Tiespectus comes in both low and high doses, providing options that could better suit different severities of the condition.

Research has shown that tiespectus, a new treatment for neovascular age-related macular degeneration (NVAMD), appears promising. In this trial, participants will receive either a low or high dose of tiespectus. Studies found that about 94% of patients taking higher doses of tiespectus experienced stable or improved eye conditions over three months. This treatment supports eye health and stabilizes vision. Early results suggest tiespectus might work as well as aflibercept, another treatment option in this trial and a common treatment for NVAMD. Some patients have reported better vision and healthier eye tissue, with no serious side effects. Overall, tiespectus could be a promising option for people with NVAMD.¹²⁴⁶⁷